Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma - A systematic review

Cancer Treatment Reviews

Volumn 41, Issue 10, 2015, Pages 925-934

  Clement, S C ^a   Peeters, R P ^b   Ronckers, C M ^a   Links, T P ^c   Van Den Heuvel Eibrink, M M ^d   Nieveen Van Dijkum, E J M ^a   Van Rijn, R R ^a   Van Der Pal, H J H ^a,e   Neggers, S J ^b   Kremer, L C M ^a   Van Eck Smit, B L F ^f   Van Santen, H M ^g  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Department of Radiation Oncology   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adverse effects; Complications; Differentiated thyroid carcinoma; I 131; Radioactive iodine; Second primary malignancies

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ADVERSE OUTCOME; ARTICLE; CANCER RADIOTHERAPY; DIFFERENTIATED THYROID CANCER; DISEASE SEVERITY; HUMAN; LACRIMAL GLAND DISEASE; OUTCOME ASSESSMENT; RISK ASSESSMENT; SALIVARY GLAND DISEASE; SALIVARY GLAND FUNCTION; SECOND CANCER; SYSTEMATIC REVIEW; THERAPY EFFECT; CARCINOMA; EYE DISEASES; FEMALE; GONADAL DISORDERS; INFERTILITY, FEMALE; LACRIMAL APPARATUS; MALE; OLIGOSPERMIA; RADIATION INDUCED NEOPLASM; SALIVARY GLAND DISEASES; THYROID NEOPLASMS;

CARCINOMA; EYE DISEASES; FEMALE; GONADAL DISORDERS; HUMANS; INFERTILITY, FEMALE; IODINE RADIOISOTOPES; LACRIMAL APPARATUS; MALE; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; OLIGOSPERMIA; SALIVARY GLAND DISEASES; THYROID NEOPLASMS;

EID: 84958913028     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.09.001     Document Type: Review

References (48)

1. SEER stat fact sheets: thyroid cancer. Surveillance Epidemiology and End Results (SEER) program. [assessed 13.02.15].
2. Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 2009;156:167-72.
3. Martínez Trufero J, Capdevilla J, Cruz JJ, Isla D. SEOM clinical guidelines for the treatment of thyroid cancer. Clin Transl Oncol 2011;13:574-9.
4. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
5. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
6. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20-37.
7. Dingle IF, Mishoe AE, Nguyen SA, Overton LJ, Gillespie MB. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer. Otolaryngol Head Neck Surg 2013;148:746-52.
8. Fard-Esfahani A, Mirshekarpour H, Fallahi B, Eftekhari M, Saghari M, Beiki D, et al. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. Clin Nucl Med 2007;32:696-9.
9. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-44.
10. Wichers M, Benz E, Palmedo H, Biersack HJ, Grünwald F, Klingmüller D. Testicular function after radioiodine therapy for thyroid carcinoma. Eur J Nucl Med 2000;27:503-7.
11. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 2001;86:3512-5.
12. Fard-Esfahani A, Hadifar M, Fallahi B, Beiki D, Eftekhari M, Saghari M, et al. Radioiodine treatment complications to the mother and child in patients with differentiated thyroid carcinoma. Hell J Nucl Med 2009;12:37-40.
13. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia PA: Lippincott Raven; 1998.
14. Dutch Cochrane Centre risk of bias tool. .
15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
16. Sioka C, Kouraklis G, Zafirakis A, Manetou A, Dimakopoulos N. Menstrual cycle disorders after therapy with iodine-131. Fertil Steril 2006;86:625-8.
17. Brandão CD, Miranda AE, Corrêa ND. Sieiro Netto L, Corbo R, Vaisman M. Radioiodine therapy and subsequent pregnancy. Arq Bras Endocrinol Metabol 2007;51:534-40.
18. An YS, Yoon JK, Lee SJ, Song HS, Yoon SH, Jo KS. Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer. Ann Nucl Med 2013;27:386-91.
19. Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Thyroid 2013;23:609-16.
20. Lee SM, Lee JW, Kim SY, Han SW, Bae WK. Prediction of risk for symptomatic sialadenitis by post-therapeutic dual (131)I scintigraphy in patients with differentiated thyroid cancer. Ann Nucl Med 2013;27:700-9.
21. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol) 2007;19:83-6.
22. Raza H, Khan AU, Hameed A, Khan A. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy. Nucl Med Commun 2006;27:495-9.
23. Esfahani AF, Fallahi B, Olamaie R, Eftekhari M, Beiki D, Saghari M. Semiquantitative assessment of salivary gland function in patients with differentiated thyroid carcinoma after radioiodine-131 treatment. Hell J Nucl Med 2004;7:206-9.
24. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 2002;27:767-71.
25. Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys 1996;35:535-40.
26. Zettinig G, Hanselmayer G, Fueger BJ, Hofmann A, Pirich C, Nepp J, et al. Longterm impairment of the lacrimal glands after radioiodine therapy: a crosssectional study. Eur J Nucl Med Mol Imaging 2002;29:1428-32.
27. Canale D, Ceccarelli C, Caglieresi C, Moscatelli A, Gavioli S, Santini P, et al. Effects of radioiodine treatment for differentiated thyroid cancer on testis function. Clin Endocrinol (Oxf) 2015;82:295-9.
28. Rosário PW, Barroso AL, Rezende LL, Padrão EL, Borges MA, Guimarães VC, et al. Testicular function after radioiodine therapy in patients with thyroid cancer. Thyroid 2006;16:667-70.
29. Esfahani AF, Eftekhari M, Zenooz N, Saghari M. Gonadal function in patients with differentiated thyroid cancer treated with (131)I. Hell J Nucl Med 2004;7:52-5.
30. Pacini F, Gasperi M, Fugazzola L, Ceccarelli C, Lippi F, Centoni R, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994;35:1418-22.
31. Souza Rosário PW, Alvarenga Fagundes T, Villas-Boas Fagundes AS, Barroso AL, Lamego Rezende L, Lanza Padrão E, et al. Ovarian function after radioiodine therapy in patients with thyroid cancer. Exp Clin Endocrinol Diabetes 2005;113:331-3.
32. Raymond JP, Izembart M, Marliac V, Dagousset F, Merceron RE, Vulpillat M, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab 1989;69:186-90.
33. Wu JX, Young S, Ro K, Li N, Leung AM, Chiu HK, et al. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for welldifferentiated thyroid cancer. Thyroid 2015;25:133-8.
34. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbé M, Ceccarelli C, et al. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med 2008;49:845-52.
35. Chow SM, Yau S, Lee SH, Leung WM, Law SC. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment. Int J Radiat Oncol Biol Phys 2004;59:992-1000.
36. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995;36:21-7.
37. Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131) I dose over 37 GBq. Clin Endocrinol (Oxf) 2015;23:220-7.
38. Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery 2012;151:844-50.
39. Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, Larijani B, et al. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med 2011;36:277-82.
40. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504-15.
41. Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, et al. Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2004;31:685-91.
42. Helman J, Turner RJ, Fox PC, Baum BJ. 99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl- co-transport system. J Clin Invest 1987;79:1310-3.
43. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 1998;83:1746-51.
44. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011;21:1081-125.
45. Verkooijen RB, Smit JW, Romijn JA, Stokkel MP. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 2006;155:801-6.
46. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005;46:261-6.
47. Ma C, Xie J, Chen Q, Wang G, Zuo S. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. Cochrane Database Syst Rev 2009:CD007956.
48. Fallahi B, Beiki D, Abedi SM, Saghari M, Fard-Esfahani A, Akhzari F, et al. Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? Nucl Med Commun 2013;34:777-86.